Literature DB >> 6277407

Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users.

A Ohlsson, J E Lindgren, A Wahlén, S Agurell, L E Hollister, H K Gillespie.   

Abstract

Deuterium labelled delta 1-tetrahydrocannabinol was administered intravenously (5.0 mg) and by smoking (10.0 mg) to five heavy and four light marihuana users. All subjects smoked an estimated amount of 8.6-9.9 mg delta 1-tetrahydrocannabinol. The plasma levels of delta 1-tetrahydrocannabinol were followed for 48 hours and in two subjects fof 72 hours after administration. The systemic availability after inhalation calculated from the area under curve values was in the range of 27 +/- 10% for the heavy users and 14 +/- 1% for the light users. There was little difference between the groups with regard to the amount of smoked delta 1-tetrahydrocannabinol or plasma levels and area under curve values obtained after i.v. administration. Thus, it seems likely that the statistically significant difference in systemic availability of smoked delta 1-tetrahydrocannabinol was due to a more efficient smoking by the heavy users. It is also indicated that heavy users prefer slightly higher delta 1-tetrahydrocannabinol plasma levels than light users. Based on the area under curve values after i.v. administration, a plasma clearance of 760-1190 ml min-1 was calculated. The elimination half-life of delta 1-tetrahydrocannabinol is more than 20 hours. The present results do not suggest that tolerance or sensitivity to delta 1-tetrahydrocannabinol in heavy users is readily achieved.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277407     DOI: 10.1002/bms.1200090103

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  18 in total

1.  Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Authors:  Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-11-15       Impact factor: 8.327

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 3.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

4.  Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Authors:  Stephanie Lunn; Patrick Diaz; Shannon O'Hearn; Shaina P Cahill; Alexia Blake; Kelly Narine; Jason R B Dyck
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

5.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

6.  Kinetic study of smoking marijuana.

Authors:  G Barnett; C W Chiang; M Perez-Reyes; S M Owens
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

7.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.

Authors:  Claudine C Hunault; Tjeert T Mensinga; Irma de Vries; Hermien H Kelholt-Dijkman; Jani Hoek; Maaike Kruidenier; Marianne E C Leenders; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-08-10       Impact factor: 4.530

10.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.